TS-075241 — Problem Cardiovascular diseases (CVDs) such as heart failure, myocardial infarction, and cardiomyopathies remain leading causes of death worldwide. Notably, heart failure is the only major cardiovascular condition still increasing in prevalence. Current treatments primarily consist in managing the …

TS-075179 — Problem Mitochondria is a promising target for cancer treatment. However, current strategies to specifically and effectively destroy cancer mitochondria in vivo are limited. Solution Applications Competitive Advantages Seeking Opportunities for Licensing and collaboration

TS-075164 — The Problem Treatments for inherited retinal diseases are currently limited. Gene therapy has emerged as a strong treatment option. However, difficulties have arisen with these gene therapies. It has been found that an intrathecal injection of adenoassociated viral (AAV) gene therapy vector does no…

TS-075160 — Problem Peripheral neuropathy (PN) results in loss of innervation by the peripheral nerves in tissues such as skin, muscle, heart and subcutaneous white adipose tissue (scWAT). It is mostly associated with diabetes, obesity, aging, and chemotherapy. Affecting 10-20% of U.S. adults aged 50-70, PN is…

TS-074218 — This HIV-focused technology introduces a novel strategy for engaging conserved viral biology that is not directly addressed by existing antiretroviral classes. By expanding the range of actionable HIV mechanisms, the approach creates new opportunities for therapeutic discovery, combination strategies, and next‑generation intervention concepts. The technology is designed to complement current HIV treatment paradigms while supporting diversification of long‑term antiviral pipelines.

TS-066100 — Research tool to transfect cells ex vivo using electroporation through electrospun core-shell fibers for research applications

TS-066052 — Novel T-cells expressing the IL-2a receptor to enhance cancer cell targeting.

TS-065913 — Gene therapy strategies for treating peripheral neuropathy.

TS-063091 — A gene therapy approach to address the specific needs of failing hearts.

TS-062096 — Using tissue nano-transfection to regulate BAT and increase 12,13-diHOME production to treat obesity, cardiovascular disease and type 2 diabetes.